From Spatial Heterogeneity to Real-Time Monitoring: Liquid Biopsy for Genomic Profiling and MRD Assessment in Multiple Myeloma
Blood tests capturing tumor DNA and cells offer richer information than bone marrow alone about multiple myeloma's spread and resistance, pending standardization for routine use.
This review comprehensively examines liquid biopsy components (ctDNA, CTCs) as adjuncts to conventional bone marrow assessments in multiple myeloma, demonstrating their utility for capturing spatial heterogeneity, detecting treatment resistance mutations, and monitoring minimal residual disease including extramedullary relapse. Current limitations including assay variability and lack of standardization prevent routine clinical implementation.
What the study was
- Study design
- Narrative review
- Population
- Multiple myeloma patients
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Cancers (Basel)
Why it surfaced
Comprehensive review in a clinically important area; no novel primary data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.